Statin Intolerant Hypercholesterolemia Therapeutics
1. Nexletol patent expiration
Treatment: Use of nexletol as an adjunct to diet and maximally tolerated statin therapy to lower ldl-c in adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular dise...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7335799 | ESPERION | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2030
(4 years from now) | |
| US11613511 | ESPERION | Methods of making bempedoic acid and compositions of the same |
Jun, 2040
(14 years from now) | |
| US12404227 | ESPERION | Methods Of Making Bempedoic Acid And Compositions Of The Same |
Jun, 2040
(14 years from now) | |
| US12398087 | ESPERION | Methods Of Making Bempedoic Acid And Compositions Of The Same |
Jun, 2040
(14 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10118881 | ESPERION | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2023
(2 years ago) | |
| US8497301 | ESPERION | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2023
(2 years ago) | |
| US10941095 | ESPERION | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2023
(2 years ago) | |
| US9000041 | ESPERION | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2023
(2 years ago) | |
| US9624152 | ESPERION | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2023
(2 years ago) | |
| US11744816 | ESPERION | Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease |
Mar, 2036
(10 years from now) | |
| US11926584 | ESPERION | Methods of making bempedoic acid and compositions of the same |
Jun, 2040
(14 years from now) | |
| US11760714 | ESPERION | Methods of making bempedoic acid and compositions of the same |
Jun, 2040
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 21, 2025 |
| New Indication(I-943) | Mar 22, 2027 |
| New Indication(I-944) | Mar 22, 2027 |
Drugs and Companies using BEMPEDOIC ACID ingredient
NCE-1 date: 22 February, 2024
Market Authorisation Date: 21 February, 2020
Dosage: TABLET
How can I launch a generic of NEXLETOL before it's drug patent expiration?
More Information on Dosage
NEXLETOL family patents
